Sukumar Nagendran

Sukumar Nagendran has a diverse work experience in the biotechnology and healthcare sector. Sukumar is currently the President of Taysha Gene Therapies and has been serving as an Independent Director and Chair of the Compensation Committee since September 2020. Sukumar is also a Member of the Audit Committee in the same company. Sukumar Nagendran holds positions as a Board Member in Saliogen, Project Healthy Minds, and Medocity, Inc. Sukumar is also a Member of the Board of Directors in RTW Investments SPAC, Neurogene, Inc., and Solid Biosciences. In addition, they have worked as a Special Advisor in Chardan and as an Advisor in Encoded Therapeutics. Previously, Sukumar Nagendran served as the President, R&D, and Chief Medical Officer of Jaguar Gene Therapy from February 2020 to February 2023. Overall, Sukumar Nagendran has extensive experience and expertise in the biotech and healthcare industry.

Sukumar Nagendran's education history is as follows:

Sukumar Nagendran began their education at Royal College from 1971 to 1983, where they completed their Advanced Level Exam in Zoology, Chemistry, Physics, and Pure Math. After that, they attended North Colombo Medical College from 1984 to 1987 and completed their 2nd MBBS exam, focusing on Anatomy, Physiology, and Biochemistry.

In 1988, Nagendran enrolled at Rutgers University and earned their Bachelor's degree (BA) in Biochemistry, Psychology, and Religion, graduating in 1990. Subsequently, they pursued higher education at Rutgers Robert Wood Johnson Medical School from 1990 to 1994 and obtained their MD degree in Medicine.

Nagendran then attended Mayo Clinic Graduate School of Biomedical Sciences from 1994 to 1997, participating in the Internal Medicine Residency Program and completing a residency in Internal Medicine. During the same period, they also received further training at Mayo Clinic in Rochester, MN in Medicine.

In 2008, Nagendran attended the Center For Management Research for a program entitled "Strategies for Enhancing Executive Influence," but no specific degree was provided.

In 2010, they obtained a certification from The Wharton School through their Executive Education for Leaders program.

Finally, in 2012, Nagendran completed a Mini MBA Program at Rutgers Business School, specializing in BioPharma Innovation.